Piramal Pharma Limited has disclosed, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that the US Food and Drug Administration (US FDA) conducted a Good Manufacturing Practices (GMP) inspection at its Sellersville, USA facility. The inspection took place from 4th May, 2026 to 8th May, 2026, and concluded with the issuance of a Form-483 carrying three observations. At the closing meeting, the inspectors recommended that the observations be classified under Voluntary Action Indicated (VAI), which is generally considered a less critical classification in the US FDA's inspection outcome framework.

Inspection Outcome and Key Details

The following table summarises the key details of the US FDA inspection and its outcome:

The company confirmed that none of the three observations are related to data integrity, further underscoring the relatively contained nature of the findings.

Company's Response and Compliance Commitment

Piramal Pharma stated that it is preparing a detailed response to the observations, which will be submitted to the US FDA within the stipulated timelines. The company reaffirmed its commitment to maintaining the highest standards of compliance and indicated it will work closely with the agency to comprehensively address all the observations.

The disclosure was made by Maneesh Sharma, Company Secretary and Compliance Officer of Piramal Pharma Limited, and was digitally signed on 10th May, 2026.

Piramal Pharma Limited has announced the schedule of an Analyst/Institutional Investor Meeting to be held on May 27, 2026, in Mumbai. The disclosure was made pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The meeting is part of the 360 ONE Capital 16th Annual Investor Conference - Trinity India 2026. The nature of the meeting is described as a Group/One-on-one Meeting (Investor Conference). The venue for the meeting is Mumbai.

The company has noted that the dates are subject to changes, which may occur due to exigencies on the part of investors or the company. The intimation was signed by Maneesh Sharma, Company Secretary & Compliance Officer of Piramal Pharma Limited, on May 4, 2026.

Piramal Pharma Limited is listed on both BSE Limited with scrip code 543635 and National Stock Exchange of India Limited with symbol PPLPHARMA. The registered office of the company is located at Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070, Maharashtra, India.

Meeting Details

The scheduled meeting represents part of the company's ongoing engagement with the investment community. The 360 ONE Capital 16th Annual Investor Conference - Trinity India 2026 provides a platform for analysts and institutional investors to interact with the company's management team.

Important Note

The company has explicitly stated that the meeting dates are subject to changes. Any modifications will be communicated as necessary, depending on exigencies that may arise from either the investors' side or the company's side.

Company Information

Piramal Pharma Limited operates with its registered office at Ananta Building, Piramal Corporate Park in Kurla (West), Mumbai. The company's corporate identification number is L24297MH2020PLC338592. For any queries related to the meeting, shareholders can contact the company at shareholders.ppl@piramal.com or call +91 22 3802 3000 / 4000.

Regulatory Compliance

The intimation of the meeting schedule is in compliance with Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which requires listed companies to disclose the schedule of meetings with analysts and institutional investors to the stock exchanges.

Stock Exchange Listings

The company's securities are traded on both major stock exchanges in India: